Purple Biotech Ltd. Updates Company Presentation
Ticker: PPBT · Form: 6-K · Filed: Jul 19, 2024 · CIK: 1614744
Sentiment: neutral
Topics: company-update, investor-relations
Related Tickers: PRPL
TL;DR
Purple Biotech (PRPL) dropped an updated investor deck, check their site.
AI Summary
On July 19, 2024, Purple Biotech Ltd. announced it has made an updated Company Presentation available on its website. This presentation is attached as Exhibit 99.1 to the filing.
Why It Matters
Investors can access the latest company information and strategic updates directly from Purple Biotech Ltd.'s official channels.
Risk Assessment
Risk Level: low — This filing is an informational update regarding a company presentation and does not contain significant financial or operational news.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- July 19, 2024 (date) — Announcement Date
- Exhibit 99.1 (document) — Attached Presentation
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to announce that Purple Biotech Ltd. has made an updated Company Presentation available on its website.
When was the updated Company Presentation made available?
The updated Company Presentation was made available on July 19, 2024.
Where can investors find the updated Company Presentation?
The updated Company Presentation is available on Purple Biotech Ltd.'s website and is attached as Exhibit 99.1 to this filing.
What is the Commission File Number for Purple Biotech Ltd.?
The Commission File Number for Purple Biotech Ltd. is 001-37643.
What is the principal executive office address for Purple Biotech Ltd.?
The principal executive office address for Purple Biotech Ltd. is 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-07-19 08:53:53
Filing Documents
- ea0209630-6k_purplebio.htm (6-K) — 14KB
- ea020963001ex99-1_purplebio.htm (EX-99.1) — 68KB
- ex99-1_001.jpg (GRAPHIC) — 802KB
- ex99-1_002.jpg (GRAPHIC) — 1061KB
- ex99-1_003.jpg (GRAPHIC) — 409KB
- ex99-1_004.jpg (GRAPHIC) — 510KB
- ex99-1_005.jpg (GRAPHIC) — 614KB
- ex99-1_006.jpg (GRAPHIC) — 517KB
- ex99-1_007.jpg (GRAPHIC) — 613KB
- ex99-1_008.jpg (GRAPHIC) — 656KB
- ex99-1_009.jpg (GRAPHIC) — 558KB
- ex99-1_010.jpg (GRAPHIC) — 637KB
- ex99-1_011.jpg (GRAPHIC) — 458KB
- ex99-1_012.jpg (GRAPHIC) — 560KB
- ex99-1_013.jpg (GRAPHIC) — 541KB
- ex99-1_014.jpg (GRAPHIC) — 423KB
- ex99-1_015.jpg (GRAPHIC) — 469KB
- ex99-1_016.jpg (GRAPHIC) — 455KB
- ex99-1_017.jpg (GRAPHIC) — 618KB
- ex99-1_018.jpg (GRAPHIC) — 490KB
- ex99-1_019.jpg (GRAPHIC) — 596KB
- ex99-1_020.jpg (GRAPHIC) — 360KB
- ex99-1_021.jpg (GRAPHIC) — 351KB
- ex99-1_022.jpg (GRAPHIC) — 498KB
- ex99-1_023.jpg (GRAPHIC) — 476KB
- ex99-1_024.jpg (GRAPHIC) — 626KB
- ex99-1_025.jpg (GRAPHIC) — 583KB
- ex99-1_026.jpg (GRAPHIC) — 545KB
- ex99-1_027.jpg (GRAPHIC) — 610KB
- ex99-1_028.jpg (GRAPHIC) — 571KB
- ex99-1_029.jpg (GRAPHIC) — 443KB
- ex99-1_030.jpg (GRAPHIC) — 427KB
- ex99-1_031.jpg (GRAPHIC) — 600KB
- ex99-1_032.jpg (GRAPHIC) — 411KB
- ex99-1_033.jpg (GRAPHIC) — 549KB
- ex99-1_034.jpg (GRAPHIC) — 415KB
- ex99-1_035.jpg (GRAPHIC) — 699KB
- ex99-1_036.jpg (GRAPHIC) — 450KB
- ex99-1_037.jpg (GRAPHIC) — 459KB
- ex99-1_038.jpg (GRAPHIC) — 452KB
- ex99-1_039.jpg (GRAPHIC) — 481KB
- ex99-1_040.jpg (GRAPHIC) — 572KB
- ex99-1_041.jpg (GRAPHIC) — 471KB
- ex99-1_042.jpg (GRAPHIC) — 517KB
- ex99-1_043.jpg (GRAPHIC) — 282KB
- ex99-1_044.jpg (GRAPHIC) — 373KB
- ex99-1_045.jpg (GRAPHIC) — 311KB
- ex99-1_046.jpg (GRAPHIC) — 578KB
- ex99-1_047.jpg (GRAPHIC) — 499KB
- ex99-1_048.jpg (GRAPHIC) — 298KB
- ex99-1_049.jpg (GRAPHIC) — 509KB
- ex99-1_050.jpg (GRAPHIC) — 384KB
- ex99-1_051.jpg (GRAPHIC) — 383KB
- ex99-1_052.jpg (GRAPHIC) — 596KB
- ex99-1_053.jpg (GRAPHIC) — 475KB
- 0001213900-24-062768.txt ( ) — 37494KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. July 19, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2